Oncology is the future segment of the industry. With rising incidence of cancer in India and richest pipeline of new products makes this segment very attractive for our company, which is futuristic in planning its growth plans. In oncology, we have identified and launched molecules for two of the most common cancers seen in India i.e. breast cancer and Colorectal.
Lupin Oncology has launched two unique brands ieGenexol-PM (Nanoparticle Paclitaxel) and Luporal (Tegafur + Uracil) by tie-ups with Korean and Taiwanese companies.
We are constantly striving hard to connect with companies overseas for in-licensing opportunities to bring newer therapies that can improve survival of the patients in India. We also believe in launching the common protocol therapies at cost-effective prices and hence have launched LUPINIB (Imatinib) at the cost effective price compared to the other brands in the segment.
|Brand Name||Molecule||Therapy Segment|
|Genexol-PM||Nano-particle size Paclitaxel 100mg inj||Cytotoxic therapy|
|Nano-particle size Paclitaxel 30mg inj||Cytotoxic therapy|
|Luporal||Tegafur 100mg -uracil 224mg Capsule||DPD Inhibitor|
|Lupinib||Imatinib 400mg tablet||Tyrosine kinase inhibitor|
|Geftistar||Gefitinib 250 mg tablets||EGFR inhibitor|
|Chemodoc||Docetaxel INJ 120 mg||Cytotoxic therapy|
|Docetaxel INJ 20 mg||Cytotoxic therapy|
|Docetaxel INJ 80 mg||Cytotoxic therapy|
|Paclistar||Paclitaxel 100 mg Inj||Cytotoxic therapy|
|Paclitaxel 260 mg Inj||Cytotoxic therapy|
|Paclitaxel 30 mg Inj||Cytotoxic therapy|
|Femitraz||Anastrozole 1mg Tablet||Aromataze Inhibitor|
|Apristar||Aprepitant 125 mg capsules||CINV therapy|
|Aprepitant 80 mg capsules||CINV therapy|